We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Elli
Enayat
craaft-hf-cvctu@qmul.ac.uk
Pier
Lambiase
p.lambiase@ucl.ac.uk
Elli
Enayat
craaft-hf-cvctu@qmul.ac.uk
Other forms of heart disease
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Atrial fibrillation (AF) is a common heart rhythm disorder that causes an irregular heart beat and is a cause of heart failure (HF). Treatments include drugs to slow the heart rate, anti-arrhythmic drugs or ablation of the heart to help preserve normal rhythm. A number of trials have suggested that ablation may be superior to drug treatment to reduce hospitalisations or prevent early death. However, these studies have been small and the results not applicable to the general population with AF and heart failure in the UK. This international study will compare optimal medical therapy with catheter ablation versus optimal medical therapy alone to see if catheter ablation reduces unplanned heart failure hospitalisations and death rates and improves quality of life.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Interventional type: Surgery;
You can take part if:
You may not be able to take part if:
1. Long standing (> 3 year) persistent or permanent AF. 2. Previous atrioventricular (AV) nodal ablation 3. Previous pulmonary vein isolation (PVI) or surgical ablation. 4. Recent (< 90 days) (type 1 spontaneous) myocardial infarction (type 2 myocardial infarctions are not an exclusion criterion), percutaneous coronary intervention, coronary artery bypass grafting, cardiac resynchronisation therapy or stroke. 5. Severe aortic or pulmonary valve disease. 6. Severe primary or secondary mitral valve regurgitation. 7. Active illness (other than HF) likely to result in death within 2 years. 8. Women who are pregnant or planning to become pregnant during the trial (Females of childbearing potential must have a negative pregnancy test seven days or fewer prior to enrolment). 9. Females who are breastfeeding. 10. Known allergy to contrast. 11. Contraindication for PVI. 12. Other conditions that may prevent subjects from adhering to the trial protocol, in the opinion of the investigator. 13. Currently participating in another randomised controlled trial of another drug or medical device.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Elli
Enayat
craaft-hf-cvctu@qmul.ac.uk
Pier
Lambiase
p.lambiase@ucl.ac.uk
Elli
Enayat
craaft-hf-cvctu@qmul.ac.uk
The study is sponsored by University College London and funded by BRITISH HEART FOUNDATION .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 61931
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
